Vetter to build $320M plant in U.S.

When word got out last week that German CDMO Vetter would build a sterile injectables manufacturing facility in the Chicago area, details were thin. But now the company has filled them in, saying it will invest $320 million and hopes to eventually have 400 to 500 workers at the site.

Vetter is seeking approval from local authorities for permission to build out a 1.1-million-square-foot facility over a decade on an 18-acre site in Des Plaines, IL. The site used to be home to the Salvation Army’s central territory headquarters.

The facility would handle fill and finish of aseptically prefilled syringe systems, cartridges and vials and is expected to initially provide about 300 jobs, but Vetter is hoping to expand it over time. The Ravensburg, Germany-based company already has a small clinical supply facility in the nearby Village of Skokie where about 70 people work, but Vetter said it wanted to be able to offer its clients commercial manufacturing capabilities in the U.S.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“Several of our customers have requested commercial manufacturing resources both in U.S. and Europe for their multifaceted market production needs,” Vetter Managing Director Peter Soelkner said in a statement.

Vetter has been expanding for several years and in 2013 announced plans to invest about $100 million in its facilities in Ravensburg and in Skokie.  

- here’s the release 

Related Articles: 
New Chicago-area plant for Germany's Vetter promises 300 jobs 
Vetter putting $100M into its production network

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.